Apigenin, a Partial Antagonist of the Estrogen Receptor (ER), Inhibits ER-Positive Breast Cancer Cell Proliferation through Akt/FOXM1 Signaling
Approximately 80% of breast cancer (BC) cases express the estrogen receptor (ER), and 30–40% of these cases acquire resistance to endocrine therapies over time. Hyperactivation of Akt is one of the mechanisms by which endocrine resistance is acquired. Apigenin (Api), a flavone found in several plant...
Main Authors: | Thu Ha Pham, Yann Le Page, Frédéric Percevault, François Ferrière, Gilles Flouriot, Farzad Pakdel |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/1/470 |
Similar Items
-
Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
by: Sven Roßwag, et al.
Published: (2021-04-01) -
A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer
by: Léa Clusan, et al.
Published: (2023-04-01) -
Hypoxia and ERα Transcriptional Crosstalk Is Associated with Endocrine Resistance in Breast Cancer
by: Charly Jehanno, et al.
Published: (2022-10-01) -
A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses
by: Léa Clusan, et al.
Published: (2021-01-01) -
Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER
by: Rainer Girgert, et al.
Published: (2019-01-01)